This account is pending registration confirmation. Please click on the link within the confirmation email previously sent you to complete registration.
Need a new registration confirmation email? Click here
Stocks Under $10 with 50-100% upside potential - 14 days FREE!

Adam Feuerstein

Senior Columnist

Before joining TheStreet in March 2001, Feuerstein covered business software for Prior to that he covered a variety of business beats, including technology and commercial real estate, at the San Francisco Business Times.

Feuerstein graduated from Emory University with a bachelor's degree in political science.

Adam Feuerstein
By This Author:
Page 2 of 568

Retrophin CEO Under Fire for Twitter Faux Pas

By Adam Feuerstein

Retropin employees were using alias Twitter accounts -- two of which affected the persona of gangster rappers -- to promote Retrophin and pitch short-sale recommendations of other stocks to followers.

08:00AM 08/11/14

MannKind Lands Afrezza Partner but at High Cost

By Adam Feuerstein

For all the hype about Afrezza's greatness, Mann walks away with a joint venture in which he secures just one-third of Afrezza's potential profit -- and losses.

06:49AM 08/11/14

Sarepta Should Shut Up About Ebola, Focus on Job No. 1

By Adam Feuerstein

By publicizing its outreach to the U.S. government about an experimental ebola treatment, Sarepta comes off looking like just another opportunistic, self-promoting drug developer.

12:07PM 08/06/14

The Tekmira Ebola Trade May Already Be Over

By Adam Feuerstein

CNN reports competing, secret Ebola therapy already saved lives of U.S. aid workers.

10:07AM 08/04/14

Cel-Sci's Enrollment Math Doesn't Add up

By Adam Feuerstein

In order to enroll the remaining 648 patients into the Multikine study by the end of 2015, Cel-Sci needs to average 40.5 patients per month, or 121.5 patients per quarter.

11:11AM 08/01/14

Biotech Stock Mailbag: Arrowhead, Catalyst Pharma

By Adam Feuerstein

Biotech columnist Adam Feuerstein answers readers' questions about health care.

08:06AM 08/01/14

Amarin Shocker: There's a Reason to be Bullish Right Now

By Adam Feuerstein

If an FDA appeal decision goes in Amarin's favor, the stock is moving much higher.

09:02AM 07/31/14

Here's Why Aegerion and Sarepta Trade Higher Wednesday

By Adam Feuerstein

Aegerion offers brighter-than-expected sales outlook; Sarepta up on FDA response to petition.

11:22AM 07/30/14

Galectin Drug is a Fatty Liver Flop

By Adam Feuerstein

Across just about every biomarker for efficacy Galectin thought to measure, GR-MD-02 showed no difference from placebo in a phase I study.

10:26AM 07/29/14

Galectin Pays Stock Promoters to Entice Retail Investors

By Adam Feuerstein

Like Galena BioPharma and The DreamTeam Group, Galectin is also paying for a promotional campaign designed to entice retail investors into buying its stock.

12:34PM 07/28/14

Page 2 of 568

Select the service that is right for you!

Action Alerts PLUS
Try it NOW

Jim Cramer and Stephanie Link actively manage a real portfolio and reveal their money management tactics while giving advanced notice before every trade.

Product Features:
  • $2.5+ million portfolio
  • Large-cap and dividend focus
  • Intraday trade alerts from Cramer
  • Weekly roundups
TheStreet Quant Ratings
Try it NOW
Only $49.95/yr

Access the tool that DOMINATES the Russell 2000 and the S&P 500.

Product Features:
  • Buy, hold, or sell recommendations for over 4,300 stocks
  • Unlimited research reports on your favorite stocks
  • A custom stock screener
  • Upgrade/downgrade alerts
Stocks Under $10
Try it NOW

David Peltier, uncovers low dollar stocks with extraordinary upside potential that are flying under Wall Street's radar.

Product Features:
  • Model portfolio
  • Stocks trading below $10
  • Intraday trade alerts
  • Weekly roundups
Dividend Stock Advisor
Try it NOW

Jim Cramer's protege, David Peltier, identifies the best of breed dividend stocks that will pay a reliable AND significant income stream.

Product Features:
  • Diversified model portfolio of dividend stocks
  • Alerts when market news affect the portfolio
  • Bi-weekly updates with exact steps to take - BUY, HOLD, SELL
Real Money Pro
Try it NOW

All of Real Money, plus 15 more of Wall Street's sharpest minds delivering actionable trading ideas, a comprehensive look at the market, and fundamental and technical analysis.

Product Features:
  • Real Money + Doug Kass Plus 15 more Wall Street Pros
  • Intraday commentary & news
  • Ultra-actionable trading ideas
Options Profits
Try it NOW

Our options trading pros provide daily market commentary and over 100 monthly option trading ideas and strategies to help you become a well-seasoned trader.

Product Features:
  • 100+ monthly options trading ideas
  • Actionable options commentary & news
  • Real-time trading community
  • Options TV
DOW 17,048.44 +69.31 0.41%
S&P 500 1,991.30 +4.79 0.24%
NASDAQ 4,526.1550 -0.3270 -0.01%

Brokerage Partners

Free Newsletters from TheStreet

My Subscriptions:

After the Bell

Before the Bell

Booyah! Newsletter

Midday Bell

TheStreet Top 10 Stories

Winners & Losers

Register for Newsletters
Top Rated Stocks Top Rated Funds Top Rated ETFs